image credit: Freepik

Regeneron to Acquire Checkmate Pharmaceuticals in $250M Deal

April 20, 2022

Regeneron Pharmaceuticals, Inc. entered an agreement to acquire Checkmate Pharmaceuticals, Inc., a clinical stage biopharma company focused on technology to harness the immune system to combat cancer, for approximately $250 million in cash.

Checkmate’s lead investigational candidate is vidutolimod, an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonist delivered in a virus-like particle.

“As we continue to advance and expand our research efforts in immuno-oncology, the acquisition of Checkmate will add a promising new modality to Regeneron’s toolkit of potential approaches for difficult-to-treat cancers,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. “The unique combination of a differentiated Toll-like receptor 9 with other antibody-based oncology agents may result in increased clinical benefit and provide new treatment options for patients in need. We look forward to welcoming the Checkmate team and their complementary scientific acumen to the Regeneron family.”

Read More on Contract Pharma